miRNAs, piRNAs, and lncRNAs: A triad of non-coding RNAs regulating the neurovascular unit in diabetic retinopathy and their therapeutic potentials
Experimental Eye Research · 2025
DOI: 10.1016/j.exer.2025.110236 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Eye Research, 2025. Verfasst von Muthuramalingam Karpagavalli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, 605 014, India. Hauptthemen laut MEDLINE: Diabetic Retinopathy, MicroRNAs, RNA, Long Noncoding, RNA, Small Interfering. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 259 Literaturangaben. Gefördert von: Science and Engineering Research Council, Indian Council of Medical Research, University Grants Commission.
Abstract (Originalsprache)
Diabetic Retinopathy (DR), a leading complication of diabetes mellitus, has long been considered as a microvascular disease of the retina. However, recent evidence suggests that DR is a neurovascular disease, characterized by the degeneration of retinal neural tissue and microvascular abnormalities encompassing ischemia, neovascularization, and blood-retinal barrier breakdown, ultimately leading to blindness. The intricate relationship between the retina and vascular cells constitutes a neurovascular unit, a multi-cellular framework of retinal neurons, glial cells, immune cells, and vascular cells, which facilitates neurovascular coupling, linking neuronal activity to blood flow. These interconnections between the neurovascular components get compromised due to hyperglycemia and are further associated with the progression of DR early on in the disease. As a result, therapeutic approaches are needed to avert the advancement of DR by acting at its initial stage to delay or prevent the pathogenesis. Non-coding RNAs (ncRNAs) such as microRNAs, piwi-interacting RNAs, and long non-coding RNAs regulate various cellular components in the neurovascular unit. These ncRNAs are key regulators of neurodegeneration, apoptosis, inflammation, and oxidative stress in DR. In this review, research related to alterations in the expression of ncRNAs and, correspondingly, their effect on the disintegration of the neurovascular coupling will be discussed briefly to understand the potential of ncRNAs as therapeutic targets for treating this debilitating disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, 605 014, India.
- Retina Services, Aravind Eye Hospital, Puducherry, India.
- Central Inter-Disciplinary Research Facility, Sri Balaji Vidyapeeth (Deemed to be University), Puducherry, 607 402, India.
- Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, 605 014, India. Electronic address: csubbalakashmi@pondiuni.ac.in.
Förderung
- Science and Engineering Research Council
- Indian Council of Medical Research
- University Grants Commission
- Science and Engineering Research Board
Zitieren
APA
Karpagavalli, M., Sindal, M. D., Arunachalam, J. P., & Chidambaram, S. (2025). miRNAs, piRNAs, and lncRNAs: A triad of non-coding RNAs regulating the neurovascular unit in diabetic retinopathy and their therapeutic potentials. Experimental Eye Research. https://doi.org/10.1016/j.exer.2025.110236
Vancouver
Karpagavalli M, Sindal MD, Arunachalam JP, Chidambaram S. miRNAs, piRNAs, and lncRNAs: A triad of non-coding RNAs regulating the neurovascular unit in diabetic retinopathy and their therapeutic potentials. Experimental Eye Research. 2025. doi:10.1016/j.exer.2025.110236
BibTeX
@article{Karpagavalli2025,
author = {Karpagavalli, Muthuramalingam and Sindal, Manavi D and Arunachalam, Jayamuruga Pandian and Chidambaram, Subbulakshmi},
title = {miRNAs, piRNAs, and lncRNAs: A triad of non-coding RNAs regulating the neurovascular unit in diabetic retinopathy and their therapeutic potentials},
journal = {Experimental Eye Research},
year = {2025},
doi = {10.1016/j.exer.2025.110236}
}
EUVIMED